Identification of a prognostic ferroptosis-related lncRNA signature in the tumor microenvironment of lung adenocarcinoma

被引:86
作者
Guo, Yugang [1 ]
Qu, Zhongyu [2 ]
Li, Dandan [1 ]
Bai, Fanghui [2 ]
Xing, Juan [2 ]
Ding, Qian [1 ]
Zhou, Jiawei [1 ,3 ]
Yao, Lunguang [1 ]
Xu, Qian [1 ]
机构
[1] Nanyang Normal Univ, Engn Lab Insects Bioreactor, Nanyang, Henan, Peoples R China
[2] Nanyang Cent Hosp, Nanyang, Henan, Peoples R China
[3] Nanyang Normal Univ, Sch Chem & Pharmaceut Engn, Nanyang, Peoples R China
关键词
CELL-DEATH; CANCER; CHEMOTHERAPY; FORM;
D O I
10.1038/s41420-021-00576-z
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Ferroptosis is closely linked to various cancers, including lung adenocarcinoma (LUAD); however, the factors involved in the regulation of ferroptosis-related genes are not well established. In this study, we identified and characterized ferroptosis-related long noncoding RNAs (lncRNAs) in LUAD. In particular, a coexpression network of ferroptosis-related mRNAs and lncRNAs from The Cancer Genome Atlas (TCGA) was constructed. Univariate and multivariate Cox proportional hazards analyses were performed to establish a prognostic ferroptosis-related lncRNA signature (FerRLSig). We obtained a prognostic risk model consisting of 10 ferroptosis-related lncRNAs: AL606489.1, AC106047.1, LINC02081, AC090559.1, AC026355.1, FAM83A-AS1, AL034397.3, AC092171.5, AC010980.2, and AC123595.1. High risk scores according to the FerRLSig were significantly associated with poor overall survival (hazard ratio (HR)=1.412, 95% CI=1.271-1.568; P<0.001). Receiver operating characteristic (ROC) curves and a principal component analysis further supported the accuracy of the model. Next, a prognostic nomogram combining FerRLSig with clinical features was established and showed favorable predictive efficacy for survival risk stratification. In addition, gene set enrichment analysis (GSEA) revealed that FerRLSig is involved in many malignancy-associated immunoregulatory pathways. Based on the risk model, we found that the immune status and response to immunotherapy, chemotherapy, and targeted therapy differed significantly between the high-risk and low-risk groups. These results offer novel insights into the pathogenesis of LUAD, including the contribution of ferroptosis-related lncRNAs, and reveal a prognostic indicator with the potential to inform immunological research and treatment.
引用
收藏
页数:11
相关论文
共 42 条
  • [1] NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis
    Alvarez, Samantha W.
    Sviderskiy, Vladislav O.
    Terzi, Erdem M.
    Papagiannakopoulos, Thales
    Moreira, Andre L.
    Adams, Sylvia
    Sabatini, David M.
    Birsoy, Kivanc
    Possemato, Richard
    [J]. NATURE, 2017, 551 (7682) : 639 - +
  • [2] [Anonymous], 2017, LANCET, DOI [10.1001/jamaoncol.2019.2996, DOI 10.1016/S0140-6736(16)31891-8]
  • [3] Ferroptosis and Cancer: Mitochondria Meet the "Iron Maiden" Cell Death
    Battaglia, Anna Martina
    Chirillo, Roberta
    Aversa, Ilenia
    Sacco, Alessandro
    Costanzo, Francesco
    Biamonte, Flavia
    [J]. CELLS, 2020, 9 (06) : 1 - 26
  • [4] The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
    Bersuker, Kirill
    Hendricks, Joseph M.
    Li, Zhipeng
    Magtanong, Leslie
    Ford, Breanna
    Tang, Peter H.
    Roberts, Melissa A.
    Tong, Bingqi
    Maimone, Thomas J.
    Zoncu, Roberto
    Bassik, Michael C.
    Nomura, Daniel K.
    Dixon, Scott J.
    Olzmann, James A.
    [J]. NATURE, 2019, 575 (7784) : 688 - +
  • [5] HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes
    Cui, J.
    Xia, T.
    Xie, D.
    Gao, Y.
    Jia, Z.
    Wei, D.
    Wang, L.
    Huang, S.
    Quan, M.
    Xie, K.
    [J]. ONCOGENE, 2016, 35 (36) : 4708 - 4718
  • [6] FSP1 is a glutathione-independent ferroptosis suppressor
    Doll, Sebastian
    Freitas, Florencio Porto
    Shah, Ron
    Aldrovandi, Maceler
    da Silva, Milene Costa
    Ingold, Irina
    Grocin, Andrea Goya
    da Silva, Thamara Nishida Xavier
    Panzilius, Elena
    Scheel, Christina H.
    Mourao, Andre
    Buday, Katalin
    Sato, Mami
    Wanninger, Jonas
    Vignane, Thibaut
    Mohana, Vaishnavi
    Rehberg, Markus
    Flatley, Andrew
    Schepers, Aloys
    Kurz, Andreas
    White, Daniel
    Sauer, Markus
    Sattler, Michael
    Tate, Edward William
    Schmitz, Werner
    Schulze, Almut
    O'Donnell, Valerie
    Proneth, Bettina
    Popowicz, Grzegorz M.
    Pratt, Derek A.
    Angeli, Jose Pedro Friedmann
    Conrad, Marcus
    [J]. NATURE, 2019, 575 (7784) : 693 - +
  • [7] Cancer immunotherapy: the beginning of the end of cancer?
    Farkona, Sofia
    Diamandis, Eleftherios P.
    Blasutig, Ivan M.
    [J]. BMC MEDICINE, 2016, 14
  • [8] Targeting Ferroptosis to Iron Out Cancer
    Hassannia, Behrouz
    Vandenabeele, Peter
    Vanden Berghe, Tom
    [J]. CANCER CELL, 2019, 35 (06) : 830 - 849
  • [9] Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer
    Jang, Nuri
    Kwon, Hee Jung
    Park, Min Hui
    Kang, Su Hwan
    Bae, Young Kyung
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (04) : 937 - 946
  • [10] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.21492, 10.3322/caac.20115, 10.3322/caac.20107]